ProMetic Life Sciences Inc. has selected C1-INH as its next plasma-derived drug candidate to be developed. The C1-INH protein is most commonly used for the treatment of HAE. The world market for HAE reached US$1.1billion in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the market to exceed US$3 billion by 2020.
ProMetic has successfully completed the bioprocess to isolate and purify C1-INH, and has scheduled scale-up and GMP production to occur during the second half of 2015. ProMetic anticipates commencement of C1-INH clinical trial work in H1 2016.
“As anticipated, our manufacturing platform is demonstrating its ability to produce multiple high-value biopharmaceuticals simultaneously and at yield and purity levels superior to those commercially available”, declared Mr. Pierre Laurin, President and CEO of ProMetic. “We will be announcing other proteins in the coming months. Some of these will be developed and marketed with commercial partners and are already, as in the case of C1-INH, in partnering discussions”, added Mr. Laurin.